XBiotech, Inc. announced that Dr. Dirk Arnold has joined the Company’s Scientific Advisory Board (SAB). Dr. Arnold will work with XBiotech to help navigate clinical development and communicate the findings for the Company’s lead product candidate in advanced colorectal cancer. Dr. Arnold’s main research interests include the treatment of GI cancers with a focus on targeted and immunotherapies, among others. Importantly, his special interest in clinical research methodologies and benefit evaluation are relevant to one of XBiotech’s lead oncology programs, which has involved the development of a novel measure of clinical efficacy in advanced cancer patients. Dr. Arnold is a member of the following organizations: Executive Board of the European Society for Medical Oncology (ESMO) and European Cancer Organization (ECCO); chairman of Colorectal Cancer Study Group of the German Society of Clinical Oncology (AIO); American Society of Clinical Oncology (ASCO); Task Force Colorectal Cancer of the European Organization for Research and Treatment of Cancer (EORTC) GI study group; German Cancer Society; and the German Society of Haematology and Medical Oncology (DGHO). He is currently Director of the Insituto CUF de Oncologia in Lisbon, Portugal.